Target Group Inc (CBDY)
0.0053
0.00 (0.00%)
USD |
OTCM |
Apr 24, 13:44
Target Group Net Income (TTM): -0.3237M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.3237M |
September 30, 2023 | -4.060M |
June 30, 2023 | -3.990M |
March 31, 2023 | -4.706M |
December 31, 2022 | -4.520M |
September 30, 2022 | -0.6589M |
June 30, 2022 | 1.824M |
March 31, 2022 | 2.404M |
December 31, 2021 | 0.2729M |
September 30, 2021 | -5.027M |
June 30, 2021 | -11.14M |
March 31, 2021 | -12.57M |
December 31, 2020 | -7.074M |
September 30, 2020 | -7.775M |
June 30, 2020 | -4.843M |
March 31, 2020 | -6.423M |
December 31, 2019 | -10.37M |
September 30, 2019 | -3.751M |
June 30, 2019 | -4.597M |
Date | Value |
---|---|
March 31, 2019 | -3.261M |
December 31, 2018 | -1.900M |
September 30, 2018 | -3.141M |
June 30, 2018 | -1.760M |
March 31, 2018 | -0.9723M |
December 31, 2017 | -1.743M |
September 30, 2017 | -1.150M |
June 30, 2017 | -2.236M |
March 31, 2017 | -2.466M |
December 31, 2016 | -2.345M |
September 30, 2016 | -4.567M |
June 30, 2016 | -3.239M |
March 31, 2016 | -3.066M |
December 31, 2015 | -2.748M |
September 30, 2015 | -0.6719M |
June 30, 2015 | -0.5818M |
March 31, 2015 | -0.4674M |
December 31, 2014 | -0.3583M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-12.57M
Minimum
Mar 2021
2.404M
Maximum
Mar 2022
-4.596M
Average
-4.597M
Median
Jun 2019
Net Income (TTM) Benchmarks
Acasti Pharma Inc | -38.77M |
Aurinia Pharmaceuticals Inc | -78.02M |
Edesa Biotech Inc | -7.718M |
Lexaria Bioscience Corp | -5.440M |
Xenon Pharmaceuticals Inc | -182.39M |